ECAT FOUNDATION

External quality Control for Assays and Tests

With a focus on Thrombosis and Haemostasis

REPORT



SURVEY 2022-M4
Main
Labcode 1492

Copyright © 2022 ECAT Foundation



Survey: 2022-M4 Page 2 of 12 31-January-2023

Labcode: 1492

1.0.0

Version:

Date of Issue : 31-January-2023

Survey : 2022-M4

Report : Main

Note:

In the Survey Manual 2022 detailed information is given regarding the ECAT external quality assessment programme, including the statistical evaluation and explanation of the report.

This Survey Manual 2022 should be considered as an integral part of this survey report.

Please notice the information regarding the homogeneity of samples used and the between-laboratory variation on page 21 of the Survey Manual.

Complaints

Any complaints regarding this survey report should be reported to the ECAT before **March 14th**, **2023**. Complaints received after this date will not be taken into consideration.

Multiple instruments

From 2019 you have the possibility to submit per parameter results for three different instruments and or methods. However, some participants have submitted three times the same results, suggesting that this are separate results. This is **not** the case and may affect the statistical analysis. We have excluded the results from the second and third test system in the statistical analysis. Do not submit multiple times the same results anymore in future surveys.

Exclusion of results

Results < [value] or > [value] are excluded in the statistical analysis.

When other results (e.g. deviating results) are excluded in the statistical analysis, these results are placed between brackets.

This report is authorized by:

Dr. M.J. van Essen-Hollestelle Programme Expert

<u>Note</u>: A printed version of the actual Survey Manual is provided to all participants once a year. This manual can also be downloaded from the member section of the ECAT website.

ECAT Foundation

Director: Dr. P. Meijer
ECAT Office
P.O. Box 107
2250 AC Voorschoten, The Netherlands
phone +31 (0) 71 3030 910; fax + 31 (0) 71 3030 919
E-mail: info@ecat.nl
Website: www.ecat.nl
VAT number: NL802836872B01

Registration number with the Chamber of Commerce (KvK) Gouda : 41174102

General terms of delivery are applicable to all our services.



Survey: 2022-M4

Page 3 of 12 31-January-2023

Labcode: 1492

OVERVIEW Z-SCORES

1.0.0

Version:

UV:Satisfactory (-2 ≤ Z-score ≤ 2)

UV: Need attention (-3 < Z-score < -2 or 2 < Z-score < 3)

UV:Unsatisfactory (Z-score ≤ -3 or ≥ 3)
BV: Unacceptable

				_						Bivarate
Module	Parameter	Sample	Test System		Total	Assay		Method		Analysis
ADAMTS13 - I	ADAMTS13 Activty	22.193	1		-0.04		-0.21		-0.19	
		22.194	1		-0.32		0.15		0.14	



Survey: 2022-M4 Page 4 of 12

31-January-2023

Labcode:

ADAMTS13 - I

ADAMTS13 Activity

Version:

1.0.0

Sample No 22.193

Sample Details Abnormal Coagulation Control Plasma

 Prior Use
 2022-M3

 Unit
 % or IU/dL

 Expiry Date
 31-January-2024

Homogeneity 2.4 % Homogeneity Parameter APTT

For any method used for the measurement of this parameter with a CV ≤ 8.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph

on the statistical evaluation in the Survey Manual.

Number of Participants 149

Number of Responders 140 Response Rate 94 %

Comments One participant (labcode 9907191) selected the wrong unit when submitting the result. This result was

excluded in the statistical evaluation.

For the most frequently used reagents (n >= 10) the results of sample 22.193 are good comparable

with those of sample 22.153 in survey 2022-M3.

Classificatio n Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classificatio
Total	22	8	36	84	3

Your Classification Abnormal

Own Reagent											
	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Total Group	150	38	0.49	12.7	25 - 72	37.9	-0.04				
CLIA/FIA	55	39	0.65	10.0	28 - 46	37.9	-0.21				
II. Acustar ADAMTS13 activity	51	39	0.72	10.6	28 - 46	37.9	-0 19				




Version: 1.0.0

Survey: 2022-M4 Page 5 of 12

31-January-2023 Labcode: 1492

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Total Group	150	38	0.49	12.7	25 - 72
FRET	23	40	2.04	19.7	25 - 72
Homemade	10	38	4.79	31.6	25 - 72
Immucor ADAMTS13 activity	3	47			44 - 49
Other	9	39			36 - 44
Sekisui Actifluor ADAMTS13 activity	1	32			-
Enzyme Immuno Assay	66	37	0.71	12.4	29 - 51
Homemade	3	33			31 - 34
Other	1	46			-
Technoclone ADAMTS13 acitivity	61	37	0.71	11.9	29 - 51
Technoclone ADAMTS13 activity/antigen	1	39			-
Latex Immuno Assay	3	35			31 - 63
Homemade	2	47			31 - 63
Other	1	35			-
CLIA/FIA	55	39	0.65	10.0	28 - 46
Technoclone Technofluor ADAMTS13 ac	4	39			35 - 42
Other	3	36			36 - 40
Homemade	2	38			36 - 40
Other	1	36			_





Survey: 2022-M4 Page 6 of 12

31-January-2023

Labcode: 1492

ADAMTS13 - I

ADAMTS13 Activity

Version:

1.0.0

Sample No 22.194

Sample Details Plasma with an ADAMTS13 activity level between 10 and 20%

Prior Use None
Unit % or IU/dL

Expiry Date 31-December-2023

Homogeneity 3.6 % Homogeneity Parameter ADAMTS13

For any method used for the measurement of this parameter with a CV ≤ 12.0% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 149

Number of Responders 140 Response Rate 94 %

Comments One participant (labcode 9907191) selected the wrong unit when submitting the result. This result was

excluded in the statistical evaluation.

The following participants reported deviating results which were excluded in the statistical evaluation:

235: 1.6% **1086**: 0%

Classificatio n Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classificatio
Total	0	1	5	145	2

Your Classification Abnormal

Own Reagent												
	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score	
Total Group	147	13	0.24	18.4	4 - 22	11.9	-0.32					
CLIA/FIA	56	12	0.24	12.1	8 - 14	11.9	0.15					
IL Acustar ADAMTS13 activity	52	12	0.25	12.1	8 - 14	11.9	0.14					




Version: 1.0.0

Survey: 2022-M4 Page 7 of 12

31-January-2023 Labcode: 1492

Other Reagents


n	assigned value	Uncert.	CV (%)	Range
147	13	0.24	18.4	4 - 22
21	11	0.90	29.9	4 - 22
8	11			4 - 22
3	7.0			6.0 - 18.0
9	12			9 - 13
1	18			-
64	14	0.29	13.2	7 - 20
2	11			11 - 11
1	16			-
61	14	0.27	12.0	7 - 20
3	10			9 - 12
2	9.5			9.0 - 10.0
1	12			-
56	12	0.24	12.1	8 - 14
4	12			9 - 13
3	15			14 - 19
2	17			14 - 19
1	15			-
	147 21 8 3 9 1 64 2 1 61 3 2 1 56 4 3	value 147 13 21 11 8 11 3 7.0 9 12 1 18 64 14 2 11 1 16 61 14 3 10 2 9.5 1 12 56 12 4 12 3 15 2 17	value 147 13 0.24 21 11 0.90 8 11 3 7.0 9 12 1 18 64 14 0.29 2 2 11 1 16 61 14 0.27 3 3 10 2 9.5 1 12 56 12 0.24 4 12 3 15 2 17	value 147 13 0.24 18.4 21 11 0.90 29.9 8 11 3 7.0 9 12 1 18 64 14 0.29 13.2 2 11 1 16 61 14 0.27 12.0 3 10 2 9.5 1 12 56 12 0.24 12.1 4 12 3 15 2 17



IL Acustar
Overall

Version: 1.0.0

Survey: 2022-M4 Page 8 of 12 31-January-2023 Labcode: 1492





Survey: 2022-M4

Page 9 of 12 31-January-2023 Labcode: 1492

ADAMTS13 - I

ADAMTS13 antigen

Version:

1.0.0

Sample No 22.193

Sample Details Abnormal Coagulation Control Plasma

 Prior Use
 2022-M3

 Unit
 IU/mL

Expiry Date 31-January-2024

Homogeneity 2.4 % Homogeneity Parameter APT

For any method used for the measurement of this parameter with a $CV \le 8.0\%$ the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph

on the statistical evaluation in the Survey Manual.

Number of Participants 149

Number of Responders 17 Response Rate 11 %

Comments The following participant reported a deviating result which was excluded in the statistical evaluation:

1167: 0.29%


For the most frequently used reagents (n >= 10) the results of sample 22.193 are good comparable

with those of sample 22.153 in survey 2022-M3.


Classificatio n Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classificatio
Total	10	2	3	2	0

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Enzyme Immuno Assay	16	0.49	0.02	15.5	0.36 - 0.60
Technozym ADAMTS13 activity/antigen	4	0.46			0.36 - 0.49
Technozym ADAMTS13 antigen	12	0.50	0.03	14.5	0.36 - 0.60









1.0.0

Survey: 2022-M4 Page 10 of 12

31-January-2023 Labcode: 1492

ADAMTS13 - I

ADAMTS13 antigen

Version:

Sample No 22.194

Sample Details Plasma with an ADAMTS13 activity level between 10 and 20%

Prior Use None Unit IU/mL

Expiry Date 31-December-2023

Homogeneity 3.6 % Homogeneity Parameter ADAMTS13

For any method used for the measurement of this parameter with a CV ≤ 12.0% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 149


Number of Responders 17 Response Rate 11 %


Comments None.

Classificatio n Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classificatio
Total	0	0	0	17	0

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Enzyme Immuno Assay	17	0.14	0.00	10.9	0.05 - 0.17
Technozym ADAMTS13 activity/antigen	4	0.14			0.12 - 0.17
Technozym ADAMTS13 antigen	13	0.14	0.00	9.4	0.05 - 0.16






Overall



Version: 1.0.0

Survey: 2022-M4 Page 11 of 12 31-January-2023 Labcode: 1492





1.0.0 Version:

Survey: 2022-M4 Page 12 of 12 31-January-2023

Labcode:

1492